← Back to Search

Whole Health Empowerment for Endotypes of Lupus: Improving Quality of Life in SLE (WHEEL Trial)

N/A

Waitlist Available

Led By Jennifer Rogers, MD

Research Sponsored by Duke University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

1. ACR/EULAR (American College of Rheumatology) criteria for SLE;

2. ability to speak and read English;

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 5-months post baseline, and 10-month post-baseline

Awards & highlights

No Placebo-Only Group

Summary

For people living with people living with systemic lupus erythematosus (SLE) the symptoms with the largest impact on their quality of life - fatigue, pain, and brain fog - are not always addressed in rheumatology clinic visits. To address the quality-of-life limitations, the investigators have created and will test the health coach-led, 8-session Whole Health Empowerment for Endotypes of Lupus (WHEEL) online support program. This program moves beyond traditional clinic visits and standard educational curricula to engage patients in creating their own health goals and therapeutic plans in a setting that emphasizes both the psychosocial and clinical factors contributing to disease. Participants will attend the virtual sessions, work with their health coach on two additional sessions, and complete surveys.

Eligible Conditions

Systemic Lupus Erythematosus

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 5-months post baseline, and 10-month post-baseline

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 5-months post baseline, and 10-month post-baseline

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 5-months post baseline, and 10-month post-baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Intervention Adherence

Participant Satisfaction

Survey Completion

Secondary study objectives

Participant Accrual

Participant Attrition

Other study objectives

Change in LupusPro

Change in Whole Health Assessment

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Group 2: Wait-List Control (Delayed Intervention)Experimental Treatment1 Intervention

Group 2: Wait-List Control (Delayed Intervention) does not get the intervention while Group 1 is getting the intervention. Group 2 receives the intervention AFTER Group 1 has completed the intervention.

Group II: Group 1: Immediate TreatmentExperimental Treatment1 Intervention

Group 1 participants receive the intervention first which is completing the 4-month program. They will receive an additional survey when Group 2 completes the intervention.

0 / 4Eligibility criteria met